Corrigendum to “Composite hydrogel contact lens systems for naringenin: A comparison of drug loading and release behaviour in drug carrier systems” [J. Drug Deliv. Sci. Technol. 102-A (2024) 106375]: A comparison of drug loading and release behaviour in drug carrier systems” [J. Drug Deliv. Sci. Technol. 102-A (2024) 106375] (Journal of Drug Delivery Science and Technology (2024) 102(PA), (S177322472401044X), (10.1016/j.jddst.2024.106375))

The authors regret an error in missing the manuscript “Abstract” and the “Keywords” in the final published article. Both the abstract and keywords for the published article should read as follows: Abstract: Naringenin (NAR), due to its poor aqueous solubility and ocular bioavailability, faces hindrances in clinical applications for eye diseases like age-related macular degeneration (AMD). Herein, NAR-loaded Sulfobutylether-β-Cyclodextrin (SBE-β-CD) and chitosan nanoparticles (CS-NPs) embedded within hydrogel contact lenses (HyCLs) have been prepared employing a commercial standard thermal curing approach to achieve topical sustained NAR release. NAR:SBE-β-CD complexes, NAR:CS-NPs and composite HyCL systems were examined using HPLC, thermal analyses, FT-IR and NMR spectroscopy and particle size analysis. 98.1 ± 2.4 % and 37.4 ± 4 % of loaded NAR was observed in NAR:SBE-ß-CD complexes and NAR:CS-NPs, respectively. HyCL:CD and HyCL:NP properties were analysed as per ISO testing in comparison to those of commercial lenses. These lenses displayed >74 % water content and >97 % light transmission with refractive index of 1.375, tensile strengths of 0.73–0.83 MPa, and average lens diameter of 13.85 ± 0.13 mm. Diffusion-controlled NAR release of 45.95 ± 2.06 and 45.96 ± 5.18 μg/day was observed in vitro from HyCL:CD and HyCL:NP, respectively. Released amounts of NAR were within the estimated therapeutic window for the drug. Results indicated that developed composite HyCL systems show potential to be a promising ocular drug delivery system (ODDS) for the in situ prevention of AMD. Keywords Cyclodextrin; Chitosan; Contact lens, Controlled release” The authors would like to apologise for any inconvenience caused.